Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 43 | 51 | +8 |
| Shares | 13.1M | 13.2M | +137.4K (+1.1%) |
| Value | $294.2M | $222.2M | −$72.0M (−24.5%) |
New holders (9)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 1,417,157 | $23.8M | 2.03% |
| Tang Capital Management LLC | 300,000 | $5.05M | 1.02% |
| DLD Asset Management, LP | 32,500 | $547.0K | 0.04% |
| Citadel Advisors LLC | 25,101 | $422.0K | 0.00% |
| J. Goldman & Co LP | 10,544 | $177.0K | 0.01% |
| Barclays PLC | 2,593 | $44.0K | 0.00% |
| Amalgamated Bank | 1,306 | $22.0K | 0.00% |
| Amalgamated Financial Corp. | 1,306 | $22.0K | 0.00% |
| FMR LLC | 44 | $1.00K | 0.00% |
Sold out (1)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Frazier Management LLC | 1,417,157 | $31.9M |